Liquid biopsy has emerged as a promising non-invasive method for
detecting and monitoring hematologic malignancies through the analysis
of circulating tumor DNA (ctDNA) and other biomarkers in the blood.
While the technique has shown potential for improving diagnosis,
prognosis, minimal residual disease detection, therapeutic monitoring,
and research in hematologic malignancies, there are still challenges
that must be addressed, including improving sensitivity and specificity,
optimizing mutation detection, and reducing costs. With continued
advances, liquid biopsy has the potential to revolutionize the way
hematologic malignancies are diagnosed and treated.